Drugs That Distort the % Free PSA Test

What % Free PSA Actually Measures

Percent Free PSA represents the proportion of prostate-specific antigen circulating in your bloodstream without being bound to carrier proteins like alpha-1-antichymotrypsin. Total PSA alone cannot distinguish between cancer and benign prostatic hyperplasia (BPH), which is why the free-to-total ratio exists as a reflex test.

PSA enters the blood in two forms. The "complexed" fraction binds tightly to serum proteins and tends to be higher in prostate cancer. The "free" fraction floats unbound and is proportionally higher in BPH. When total PSA falls in the diagnostic gray zone of 4.0 to 10.0 ng/mL, a % Free PSA below 10% carries a cancer probability of roughly 56%, while a value above 25% drops that probability to approximately 8% [1]. The AUA/SUO guidelines endorse % Free PSA as one of several secondary biomarkers to help reduce unnecessary biopsies in the gray zone [2].

This ratio is sensitive to anything that changes either the numerator (free PSA) or the denominator (total PSA) disproportionately. That sensitivity makes drug interference a real clinical problem.

5-Alpha Reductase Inhibitors: The Biggest Offender

Finasteride (Proscar, 5 mg) and dutasteride (Avodart, 0.5 mg) reduce total PSA by a median of 50% after 6 to 12 months of therapy. This is well-documented. What clinicians sometimes overlook is the effect on the free fraction.

In a study of 308 men on finasteride published in Urology, the free-to-total PSA ratio increased by a mean of 1.9 percentage points after 12 months of treatment, potentially pushing borderline values into a falsely reassuring range [3]. The Prostate Cancer Prevention Trial (PCPT), which enrolled 18,882 men, confirmed that finasteride reduced prostate cancer incidence by 24.8% but also altered the operating characteristics of PSA-based screening [4].

The standard clinical correction is straightforward: double the measured PSA value in any man who has been on a 5-alpha reductase inhibitor for 6 months or longer. But this "doubling rule" applies to total PSA. No validated correction factor exists for % Free PSA under 5-alpha reductase inhibitor use. Dr. William Catalona, who helped develop the free PSA assay, has noted: "The ratio of free to total PSA is less reliable in patients taking finasteride or dutasteride. Clinicians should interpret these values with caution and consider additional biomarkers" [5].

Dutasteride inhibits both type 1 and type 2 5-alpha reductase isoenzymes, producing a PSA reduction of 52.4% at 24 months in the REDUCE trial (N=6,729) [6]. The effect on % Free PSA is directionally similar to finasteride but may be slightly more pronounced because of dual-isoenzyme inhibition.

Testosterone and Androgen Therapy

Exogenous testosterone, whether injected, applied topically, or delivered via pellet, increases total PSA because androgens stimulate prostatic epithelial cell growth. A meta-analysis in The Journal of Clinical Endocrinology & Metabolism found that testosterone replacement therapy raised PSA by a mean of 0.30 ng/mL within the first 12 months [7]. The Endocrine Society's 2018 clinical practice guideline recommends checking PSA at 3, 6, and 12 months after starting testosterone therapy, then annually [8].

The effect on % Free PSA is less thoroughly studied. A smaller prospective analysis of 103 hypogonadal men showed that while total PSA rose, the free fraction decreased by a relative 3% to 7% over 12 months, which could shift borderline ratios toward the cancer-suspicious range [9]. This creates an interpretive challenge: a man on TRT whose % Free PSA drops below 10% may be flagged for biopsy when the shift is pharmacologic, not pathologic.

Clinicians managing men on testosterone should establish a baseline total and free PSA before initiating therapy. Any rise in total PSA exceeding 1.4 ng/mL over 12 months, or a % Free PSA that drops below 10%, should prompt referral to urology regardless of the testosterone dose.

Biotin: The Supplement That Breaks the Assay

Biotin (vitamin B7) does not affect the prostate at all. It breaks the test itself. Many modern PSA immunoassays, including several Roche Elecsys and Siemens Atellica platforms, use streptavidin-biotin chemistry. When circulating biotin levels are high, the assay produces falsely low total PSA and falsely high free PSA, or the reverse, depending on the assay architecture (competitive vs. sandwich format).

The FDA issued a safety communication in November 2017 warning that biotin interference had caused at least one death related to a falsely low troponin result [10]. PSA is equally vulnerable. At biotin doses of 10 mg/day (commonly found in hair, skin, and nail supplements), the interference can distort total PSA by more than 30% on affected platforms.

The fix is simple. Stop biotin at least 72 hours before any PSA blood draw. Some laboratories require a 7-day washout for doses above 10 mg. Dr. Dara Lee Lewis of the FDA's Center for Devices and Radiological Health stated in the 2017 communication: "We want to raise awareness that biotin can significantly interfere with certain lab tests and cause incorrect test results" [10].

If your % Free PSA result seems inconsistent with your clinical picture, ask your lab which assay platform was used and whether it employs streptavidin-biotin technology.

GnRH Agonists and Antagonists

Gonadotropin-releasing hormone (GnRH) agonists like leuprolide (Lupron) and goserelin (Zoladex), along with GnRH antagonists like degarelix (Firmagon) and relugolix (Orgovyx), are used for advanced prostate cancer and sometimes for severe BPH. These drugs suppress testosterone to castrate levels (below 50 ng/dL), which drives PSA down to near zero.

Under these conditions, % Free PSA becomes clinically meaningless because both total and free PSA may fall below the assay's lower limit of detection. A study in European Urology showed that after 3 months of androgen deprivation therapy, median PSA declined from 45.6 ng/mL to 0.6 ng/mL [11]. At these levels, calculating a free-to-total ratio produces unstable results with no diagnostic value.

Men on GnRH therapy who are being monitored for biochemical recurrence should rely on ultrasensitive PSA assays measuring total PSA rather than the % Free PSA ratio.

Statins: A Modest but Measurable Effect

HMG-CoA reductase inhibitors (statins) have been associated with small reductions in total PSA. A large analysis using NHANES data found that statin users had mean PSA values 4.1% lower than nonusers after adjusting for age, race, and BMI [12]. A prospective study in the Journal of the National Cancer Institute (N=2,579) confirmed a similar effect and suggested the mechanism may involve cholesterol-dependent intracellular signaling pathways in prostatic tissue [13].

The impact on % Free PSA specifically is less clear. One analysis found no significant change in the free-to-total ratio among statin users [14]. Given the small magnitude of the total PSA reduction (typically 0.1 to 0.3 ng/mL), statins are unlikely to shift % Free PSA enough to change clinical decision-making. They are worth noting on a medication list but should not trigger the same level of concern as 5-alpha reductase inhibitors.

Anti-Androgens and Other Prostate-Targeted Drugs

Several other medications can affect % Free PSA, though the evidence is thinner.

Bicalutamide, enzalutamide, apalutamide, and darolutamide are androgen receptor inhibitors used in prostate cancer. All suppress PSA production. In the PROSPER trial (N=1,401), enzalutamide reduced median PSA by 91.3% at 12 months in nonmetastatic castration-resistant prostate cancer [15]. Like GnRH agonists, these drugs make % Free PSA unreliable at the suppressed levels they achieve.

Saw palmetto is an herbal supplement widely used for BPH symptoms. Despite common patient concerns, a Cochrane review of 32 randomized trials found no significant effect on PSA levels compared to placebo [16]. Saw palmetto does not appear to distort % Free PSA in a clinically meaningful way.

Aspirin and NSAIDs have been studied for PSA effects with mixed results. A cohort study in Cancer (N=1,319) found that daily NSAID use was associated with a 9% to 10% lower PSA [17]. Whether this extends to the free fraction is uncertain. The effect size is small enough that NSAIDs alone should not prompt adjusted PSA interpretation.

How to Interpret % Free PSA When You Are on Medications

The clinical workflow for a medicated patient getting a % Free PSA test should follow a structured approach.

Before the blood draw, tell your provider about every medication and supplement you take. This includes over-the-counter biotin. Stop biotin at least 72 hours (ideally 7 days for high-dose formulations) before the draw. Do not stop prescription medications without discussing it with your prescriber.

After results return, the interpretation depends on the drug class:

For 5-alpha reductase inhibitors: double the total PSA value, but recognize that the % Free PSA ratio has no validated correction factor. If the adjusted total PSA is in the gray zone (4 to 10 ng/mL), consider alternative biomarkers like the Prostate Health Index (PHI) or 4Kscore, which may be less susceptible to 5-alpha reductase inhibitor interference [18].

For testosterone therapy: compare against a pre-treatment baseline. A rise in total PSA of more than 1.4 ng/mL over 12 months, or any absolute value exceeding 4.0 ng/mL, warrants urology referral per the Endocrine Society guideline [8].

For GnRH agonists/antagonists or anti-androgens: do not rely on % Free PSA. Use total ultrasensitive PSA for monitoring.

For biotin: if results seem discordant, repeat the test after a 72-hour to 7-day washout.

Normal % Free PSA Range and What the Numbers Mean

In unmedicated men with a total PSA between 4.0 and 10.0 ng/mL, the % Free PSA helps stratify cancer risk. The landmark Catalona et al. study in JAMA (N=773) established the thresholds most labs still use [1]:

• Above 25%: approximately 8% probability of prostate cancer on biopsy. Observation is often appropriate.
• 10% to 25%: intermediate risk zone. Clinical context, family history, digital rectal exam findings, and secondary biomarkers guide the decision.
• Below 10%: approximately 56% probability of cancer. Biopsy is generally recommended.

These cutoffs were derived in men not taking medications known to alter PSA kinetics. Applying them to a man on finasteride, dutasteride, or testosterone without adjustments can lead to missed cancers or unnecessary biopsies.

The USPSTF (2018 recommendation) gives PSA-based screening a grade C for men aged 55 to 69, recommending individualized decision-making [19]. The guideline does not address how concomitant medications should modify screening interpretation, which leaves that judgment to the clinician.

When to Retest and When to Refer

A single % Free PSA value on medications should never be the sole basis for a biopsy decision. Retesting after appropriate washout periods (where safe), using alternative biomarkers, or proceeding to multiparametric MRI of the prostate are all reasonable next steps.

The National Comprehensive Cancer Network (NCCN) Early Detection guidelines (v2.2025) recommend considering PHI, 4Kscore, or SelectMDx when initial PSA results are in the gray zone and clinical context adds uncertainty [20]. Men on 5-alpha reductase inhibitors whose corrected PSA exceeds 4.0 ng/mL should receive the same workup as unmedicated men with elevated PSA, with the added caveat that % Free PSA thresholds may not apply.

Men aged 40 to 54 with a family history of prostate cancer or who are of African descent should discuss earlier baseline PSA testing with their clinician, per the AUA guideline [2]. Document all medications at the time of each PSA draw so that longitudinal trends can be interpreted with the appropriate pharmacologic context.